摘要
目的:研究瑞舒伐他汀对冠脉造影(CAG)正常的急性心肌梗死(AMI)患者的疗效。方法:2013年1月~2017年12月我院的CAG正常AMI患者124例被随机均分为曲美他嗪组(在常规治疗基础上接受曲美他嗪)和联合治疗组(在曲美他嗪组基础上加用瑞舒伐他汀),两组均治疗90d。观察比较两组治疗前后血脂水平,心功能指标:LVEF、左室舒张末期内径(LVEDd)、左室收缩末期内径(LVESd);血清高敏C反应蛋白(hsCRP)、白介素(IL)-23、肿瘤坏死因子(TNF)-α水平,肱动脉内皮依赖性舒张功能(FMD),颈动脉内-中膜厚度(IMT)。结果:与曲美他嗪组比较,联合治疗组治疗后血清LDL-C [(3.05±0.32)mmol/L比(2.75±0.29)mmol/L]、TC [(5.68±0.58)mmol/L比(4.97±0.51)mmol/L]、TG [(2.02±0.21)mmol/L比(1.75±0.18)mmol/L]、hsCRP [(4.51±0.47)mg/L比(2.69±0.28)mg/L]、IL-23 [(424.53±44.22)mg/L比(312.58±32.48)mg/L]、TNF-α[(6.58±0.71)mg/L比(4.44±0.46)mg/L]水平、LVESd [(41.58±4.33)mm比(35.95±3.69)mm]、LVEDd [(54.73±5.52)mm比(48.69±4.91)mm]、IMT[(1.49±0.16)mm比(1.41±0.15)mm]降低更显著,血清HDL-C [(1.05±0.11)mmol/L比(1.25±0.13)mmol/L]水平、LVEF[(42.44±4.50)%比(47.07±4.83)%]升高更显著(P均<0.01)。结论:瑞舒伐他汀能显著改善CAG正常的AMI患者心功能、血管内皮功能,调节血脂水平,降低炎症反应,值得推广。
Objective:To study therapeutic effect of rosuvastatin on patients with acute myocardial infarction(AMI)and normal coronary angiographic(CAG)results.Methods:A total of 124 AMI patients with normal CAG results in our hospital from Jan 2013 to Dec 2017 were randomly and equally divided into trimetazidine group(received trimetazidine based on routine treatment)and combined treatment group(received rosuvastatin based on trimetazidine group),both groups were treated for 90 d.Levels of blood lipids,cardiac function indexes:LVEF,left ventricular end-diastolic dimension(LVEDd),left ventricular end-systolic dimension(LVESd);serum levels of high sensitive C reactive protein(hsCRP),interleukin 23(IL-23)and tumor necrosis factor-α(TNF-α);fore brachial artery endothelium dependent diastolic-systolic function(FMD)and carotid intima-media thickness(IMT)were observed and compared between two groups before and after treatment.Results:Compared with trimetazidine group after treatment,there were significant reductions in serum levels of LDL-C [(3.05±0.32)mmol/L vs.(2.75± 0.29)mmol/L],TC [(5.68±0.58)mmol/L vs.(4.97±0.51)mmol/L],TG [(2.02±0.21)mmol/L vs.(1.75±0.18)mmol/L],hsCRP [(4.51±0.47)mg/L vs.(2.69±0.28)mg/L],IL-23 [(424.53±44.22)mg/L vs.(312.58±32.48)mg/L]and TNF-α[(6.58±0.71)mg/L vs.(4.44±0.46)mg/L],LVESd[(41.58±4.33)mm vs.(35.95±3.69)mm],LVEDd[(54.73±5.52)mm vs.(48.69±4.91)mm]and IMT[(1.49±0.16)mm vs.(1.41±0.15)mm]and significant rise in serum level of HDL-C[(1.05±0.11)mmol/L vs.(1.25±0.13)mmol/L],LVEF[(42.44±4.50)% vs.(47.07±4.83)%]in combined treatment group(P<0.01 all).Conclusion:Rosuvastatin can significantly improve cardiac function and vascular endothelial function,regulate blood lipid levels and reduce inflammation in AMI patients with normal CAG results,which is worth extending.
作者
王媛媛
WANG Yuan-yuan(Department of Cardiology,Second Central Hospital of Baoding City,Baoding,Hebei,072750,China)
出处
《心血管康复医学杂志》
CAS
2020年第1期72-76,共5页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心肌梗死
冠状血管造影术
瑞舒伐他汀
Myocardial infarction
Coronary angiography
Rosuvastatin
Coronary angiography was normal
Cardi-ac function
Inflammatory factors
Influence
